- Home
- RARE vs IEP Comparison
RARE vs IEP Comparison
Compare RARE & IEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RARE
- IEP
- Stock Information
- Founded
- RARE 2010
- IEP 1987
- Country
- RARE United States
- IEP United States
- Employees
- RARE N/A
- IEP N/A
- Industry
- RARE Biotechnology: Pharmaceutical Preparations
- IEP Auto Parts:O.E.M.
- Sector
- RARE Health Care
- IEP Consumer Discretionary
- Exchange
- RARE Nasdaq
- IEP Nasdaq
- Market Cap
- RARE 5.2B
- IEP 6.0B
- IPO Year
- RARE 2014
- IEP 1987
- Fundamental
- Price
- RARE $46.49
- IEP $11.01
- Analyst Decision
- RARE Strong Buy
- IEP
- Analyst Count
- RARE 14
- IEP 0
- Target Price
- RARE $86.79
- IEP N/A
- AVG Volume (30 Days)
- RARE 947.6K
- IEP 1.2M
- Earning Date
- RARE 11-05-2024
- IEP 11-08-2024
- Dividend Yield
- RARE N/A
- IEP 31.76%
- EPS Growth
- RARE N/A
- IEP N/A
- EPS
- RARE N/A
- IEP N/A
- Revenue
- RARE $522,745,000.00
- IEP $10,055,000,000.00
- Revenue This Year
- RARE $27.29
- IEP N/A
- Revenue Next Year
- RARE $18.30
- IEP N/A
- P/E Ratio
- RARE N/A
- IEP N/A
- Revenue Growth
- RARE 27.44
- IEP N/A
- 52 Week Low
- RARE $37.02
- IEP $9.72
- 52 Week High
- RARE $60.37
- IEP $22.59
- Technical
- Relative Strength Index (RSI)
- RARE 36.73
- IEP 31.64
- Support Level
- RARE $43.04
- IEP $10.94
- Resistance Level
- RARE $46.98
- IEP $13.16
- Average True Range (ATR)
- RARE 2.11
- IEP 0.57
- MACD
- RARE -0.31
- IEP -0.18
- Stochastic Oscillator
- RARE 34.47
- IEP 1.56
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
About IEP Icahn Enterprises L.P.
Icahn Enterprises LP is a provider of diversified business services in the United States. The company operates its business through varied segments which include Investment, Automotive, Energy, Food Packaging, Real Estate, Pharma, and Home Fashion. Among these, the Energy segment derives the maximum revenue from the company. Geographically, it generates maximum revenue from the United States.